Skip to main content

Solution

Weight Engage: An Innovative Weight Management Solution

Get the most from pricey new obesity drugs by choosing the right coverage strategy and helping your members build lifelong healthy habits.

Preparing your plan for the GLP-1 era

Drug pipeline continues to expand

45 GLP-1/GIPs drugs indicated for obesity are in the pipeline

Weight loss drugs are expected to grow exponentially over the next 3 years. In 2023, GLP-1s represented 63% of diabetes spend, up from 38% in 2020.1 The promising outcomes of these drugs have prompted other manufacturers to pursue their own development efforts.

Drugs expected to treat more than obesity

Previously approved GLP-1s used for other cardiovascular areas

Just as important as the wave of new drugs for obesity is the expansion into other therapeutic areas. Recent clinical trials have examined treatment for sleep apnea, Alzheimer’s and kidney, heart and liver disease. Usage of this class will only expand in the coming years.

Plan sponsors need a strategic partner

Strategies are needed to balance cost, utilization and more

Given the complex and evolving nature of this class, plan sponsors need a strategic partner to help balance cost and utilization. In 2023, plan sponsors who implemented key Optum Rx management strategies saw GLP-1s contribute 50% less towards overall trend growth than for those who didn’t.2

To dig deeper on the history and future implications of this drug class, check out this white paper.

Key benefits

With an increased demand for GLP-1s, plan sponsors need an innovative weight management solution to reduce costs and improve outcomes.

Appropriate utilization

Plans have the option to cover the most at-risk obesity populations only. Guide members to achieve and sustain their weight loss goals with clinical programs designed to support responsible use of GLP-1 drugs.

Enhanced system edits

Control utilization so anti-obesity medications are only used by those who meet the criteria defined by the plan.

Member support programs

Help permanently change the behaviors contributing to obesity through behavioral support, personalized diets and exercise.

Provider guidance

Obesity specialist physicians determine an individualized weight loss plan for each member and connects them with a weight loss care team.

Strategize about anti-obesity drugs

Learn how our weight management strategies can help your organization. Contact your Optum Rx representative or complete our online form.

Related healthcare insights

E-book

How to contain GLP-1 costs

Get strategies for handling the new anti-obesity medications.

Article

Preparing your plan for the GLP-1 era

After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more. Can we afford it?

Article

GLP-1 agonists: A new class of weight loss medications

In this conversation, discover how new weight loss drugs like Wegovy are changing obesity management and their connection to diabetes.

Product information and resources

  • PDF

     

    E-book

    Balancing anti-obesity drug costs with the benefits

    Weight loss can mean better health and lower costs for plan sponsors and members alike. Investing in these expensive, but effective drugs is a balancing act – especially when more than half of the U.S. adult population is eligible for them.

    Download

Complementary solutions

Improving medication affordability

Providing you with solutions that make it easier to lower drug spend.

Driving pharmacy innovations

You need simple, intelligent and adaptive solutions for your pharmacy benefit plan – fueled by the power of Optum.

Leading the industry in transparency

We deliver accessible and clear pharmacy benefit information, transparent drug pricing, and a simplified experience for everyone we serve.
  1. Internal analysis of Optum Rx Commercial Benchmark BOB 2020 – 2023.
  2. Internal analysis of 2023 results comparing highly managed clients and Commercial BOB.